Latest News
8/18/09 Xceleron Expands Agreement with GSK
Date Posted: |
18 Aug 2009 |
Summary: |
August 18, 2009 – XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. |
Download: |
 Xceleron_GSKAgreement_8 18 09_FINAL.pdf Download |
|
GERMANTOWN, Md., August 18, 2009 – XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.
Clinical studies supported by AMS allow early investigations of the human relevancy of new drugs and novel investigational paradigms greatly enhancing the drug discovery and development process. This second agreement is focused on the rapid analyses and data turnaround for early clinical studies performed by GlaxoSmithKline or its academic and various innovator collaborators. It is complimentary to an existing agreement between the two companies in which a bioanalytical service is provided to support clinical studies for regulatory submission.
Click to see more news
